Incidence and variables predicting gleason score up-grading between trans-rectal ultrasound-guided prostate biopsies and radical prostatectomy

Urologia Internationalis

Volumn 84, Issue 2, 2010, Pages 180-184

  Bright, Elizabeth ^a   Manuel, Clare ^a   Goddard, Jonathan C ^a   Khan, Masood A ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Gleason score; Needle biopsy; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER SURGERY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; BIOPSY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY;

EID: 77949358421     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277595     Document Type: Article

References (29)

1. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997; 277: 1445-1451.
2. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW: Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003; 169: 125-129.
3. Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS: Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 2004; 172: 98-102.
4. Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-74; discussion 74-75.
5. Divrik RT, Eroglu A, Sahin A, Zorlu F, Ozen H: Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Urol Oncol 2007; 25: 376-382.
6. Emiliozzi P, Maymone S, Paterno A, Scarpone P, Amini M, Proietti G, Cordahi M, Pansadoro V: Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol 2004; 172: 2224-2226.
7. Presti JC Jr: Prostate biopsy: how many cores are enough? Urol Oncol 2003; 21: 135-140.
8. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152-157.
9. Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202; discussion 202-203.
10. Ravery V, Dominique S, Panhard X, Toublanc M, Boccon-Gibod L, Boccon-Gibod L: The 20-core prostate biopsy protocol: a new gold standard? J Urol 2008; 179: 504-507.
11. Stewart CS, Leibovich BC, Weaver AL, Lieber MM: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86-91; discussion 91-92.
12. Chan TY, Chan DY, Stutzman KL, Epstein JI: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001; 166: 2181-2184.
13. Meng MV, Elkin EP, DuChane J, Carroll PR: Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol 2006; 176: 63-68; discussion 69.
14. Miyake H, Sakai I, Harada K, Hara I, Eto H: Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy. Int J Urol 2004; 11: 402-406.
15. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007; 69: 495-499.
16. Freedland SJ, Platz EA, Presti JC, Jr., Aronson WJ, Amling CL, Kane CJ, Terris MK: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500-504; discussion 504.
17. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC, Jr., Amling CL, Freedland SJ: The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU Int 2008; 102: 1074-1079.
18. Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N: Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection. J Urol 2008; 179: 1332-1334.
19. Egevad L, Norlen BJ, Norberg M: The value of multiple core biopsies for predicting the Gleason score of prostate cancer. BJU Int 2001; 88: 716-721.
20. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF: Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 2003; 169: 136-140.
21. Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F: Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009; 73: 1087-1091.
22. Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, Jeong H, Byun SS, Lee HJ, Choe G, Lee SE: Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol 2009; 27: 271-276.
23. Richstone L, Bianco FJ, Shah HH, Kattan MW, Eastham JA, Scardino PT, Scherr DS: Radical prostatectomy in men aged > or = 70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 2008; 101: 541-546.
24. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Cookson MS: Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int 2001; 88: 722-726.
25. Chun FK, Briganti A, Shariat SF, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currlin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI: Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int 2006; 98: 329-334.
26. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, Haese A, Heinzer H, McCormack M, Huland H, Graefen M, Karakiewicz PI: Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006; 49: 820-826.
27. Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F: The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. Int J Urol 2009; 16: 526-529.
28. Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE: Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007; 109: 2432-2438.
29. Carlson GD, Calvanese CB, Kahane H, Epstein JI: Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 1998; 51: 525-529.